New drugs for early Alzheimer’s disease may allow people to live without help for up to 39 additional months, a new study ...
Biogen Inc (NASDAQ:BIIB) reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35. The company ...
Alzheimer's Disease Clinical Trial Pipeline Major pharmaceutical companies are working to advance the pipeline space and unlock the future ...
Biosimilars sales were $201.5 million, up 7% driven by Benepali, with sales of $125 million, up 16%. LEQEMBI global in-market sales in the quarter were approximately $87 million, including U.S.
TD Cowen analysts adjusted their outlook on Biogen (NASDAQ:BIIB) shares, reducing the price target to $200 from the previous $275, while sustaining a Buy rating on the stock. The revision reflects ...
Scotiabank lowered the firm’s price target on Biogen (BIIB) to $224 from $244 and keeps an Outperform rating on the shares. Fiscal year results ...
RBC Capital lowered the firm’s price target on Biogen (BIIB) to $225 from $231 but keeps an Outperform rating on the shares after its Q4 ...
Q4 2024 Earnings Call Transcript February 12, 2025 Operator: Good morning. My name is Jennifer and I will be your conference ...
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...
US researchers behind the new analysis said they hoped the findings would help patients weigh up the potential benefits of ...